Program
sunakiment
Also written as “AZD8630”, “AZD8630 (test formulation) via test inhaler” and “AZD8630 (reference formulation) via Monodose inhaler”.
Its studies are mostly in Asthma, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 50 open or running | phase 2since Jul 15, 2024 | Oct 28, 2021 | none ahead |
- Named in AstraZeneca’s own pipeline as
sunakiment (AZD8630)
, phase 2, as of Oct 30, 2026 (source).
Also a collaborator on its studies: parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 28, 2021First study: phase 1 study in AsthmaFirst studyNCT05110976 · 170 enrolled · United States, Germany, United Kingdom
- Jul 15, 2024Phase 2 study in AsthmaNCT06529419 · 537 enrolled · United States, Argentina, Belgium and more
- Jul 29, 2024Phase 1 study in AsthmaNCT06531811 · 32 enrolled · United States
- Jan 22, 2025Phase 1 study in AsthmaNCT06795906 · 24 enrolled · Germany
- Jun 11, 2025Phase 1 study in AsthmaNCT07065331 · 10 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07065331Asthma · United States | 1 | Completed | Sep 19, 2025 | 10 |
| NCT06795906Asthma · Germany | 1 | Completed | Jun 27, 2025 | 24 |
| NCT06531811Asthma · United States | 1 | Completed | Oct 3, 2024 | 32 |
| NCT06529419Asthma · United States, Argentina, Belgium and more | 2 | Completed | Feb 4, 2026 | 537 |
| NCT05110976Asthma · United States, Germany, United Kingdom | 1 | Completed | Aug 2, 2023 | 170 |
How it is read
Names in the registry
- “AZD8630”, 4 entries
- “AZD8630 (test formulation) via test inhaler”, 1 entry
- “AZD8630 (reference formulation) via Monodose inhaler”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.